Loading...
XSWXKURN
Market cap848mUSD
Dec 23, Last price  
20.20CHF
1D
0.50%
1Q
7.56%
Jan 2017
12.39%
Name

Kuros Biosciences AG

Chart & Performance

D1W1MN
XSWX:KURN chart
P/E
—
P/S
22.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
28.99%
Rev. gr., 5y
115.93%
Revenues
34m
+86.61%
4,112,0004,358,000724,00035,882,00019,723,0009,108,00022,349,0001,571,0001,100,0001,000,0001,000,0006,355,0001,061,000534,000715,0002,561,0004,039,00013,815,00017,986,00033,564,000
Net income
-14m
L-5.95%
-23,850,000-28,480,000-34,552,000-6,875,000-26,009,000-24,826,000-1,454,000-18,779,000-9,216,000-30,826,000-34,026,0006,227,000-19,744,000-16,484,000-11,693,000-11,252,000-11,520,000-7,541,000-14,595,000-13,727,000
CFO
-9m
L+20.36%
-22,682,000-27,078,000-28,674,000-4,398,000-27,895,000-15,248,000-4,685,000-8,807,000-11,537,000-19,170,000-23,758,000-2,514,000-8,893,000-10,678,000-12,838,000-10,849,000-9,239,000-5,453,000-7,348,000-8,844,000
Earnings
Mar 11, 2025

Profile

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
URL
http://www.kuros.ch/
IPO date
Oct 29, 2002
Employees
73
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
33,564
86.61%
17,986
30.19%
13,815
242.04%
Cost of revenue
35,918
23,564
16,119
Unusual Expense (Income)
NOPBT
(2,354)
(5,578)
(2,304)
NOPBT Margin
Operating Taxes
380
(1,396)
(2,013)
Tax Rate
NOPAT
(2,734)
(4,182)
(291)
Net income
(13,727)
-5.95%
(14,595)
93.54%
(7,541)
-34.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
501
6,000
BB yield
-0.39%
-12.04%
Debt
Debt current
578
416
317
Long-term debt
3,708
3,410
3,975
Deferred revenue
Other long-term liabilities
(5,073)
353
Net debt
(14,364)
(71,288)
(77,795)
Cash flow
Cash from operating activities
(8,844)
(7,348)
(5,453)
CAPEX
(317)
(400)
(374)
Cash from investing activities
(326)
(400)
(374)
Cash from financing activities
(171)
3,224
6,078
FCF
(3,430)
(4,058)
1,832
Balance
Cash
14,208
24,065
28,623
Long term investments
4,442
51,049
53,464
Excess cash
16,972
74,215
81,396
Stockholders' equity
(16,587)
(91,699)
(77,176)
Invested Capital
75,442
157,399
156,651
ROIC
ROCE
EV
Common stock shares outstanding
36,582
33,901
32,794
Price
3.49
137.41%
1.47
-23.64%
1.93
-4.70%
Market cap
127,671
156.19%
49,834
-21.06%
63,129
28.52%
EV
113,307
(21,454)
(14,666)
EBITDA
398
(2,744)
576
EV/EBITDA
284.69
7.82
Interest
186
4,317
1,383
Interest/NOPBT